Piramal Pharma Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 30 Jul 2026

Company page: Piramal Pharma share price, financials & guidance record

Piramal Pharma Limited reported a strong Q1 FY27, with all three businesses contributing to mid-to-high teen revenue growth. This led to significant EBITDA expansion and margin improvement. The company highlighted robust CDMO growth, resilient performance in hospital generics, and strong momentum in consumer healthcare, while also making progress on strategic investments and maintaining a strong compliance record.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 17.4%, net profit up 15.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	2,242	2,204	2,754	1,934	2,044 −9%	2,140 −3%	2,752 −0%	2,270 +17%
Expenses	1,900	1,866	2,193	1,827	1,885	1,944	2,291	2,075
EBITDA	342	338	561	107	159 −54%	196 −42%	461 −18%	195 +82%
Margin	15%	15%	20%	6%	8%	9%	17%	9%
Other income	78	29	58	98	80	12	-116	109
Interest	108	103	104	86	82	89	83	88
Depreciation	192	197	243	197	203	213	218	224
Profit before tax	120	67	273	-79	-46 −138%	-94 −240%	43 −84%	-7 +91%
Tax rate	81%	94%	44%	3%	115%	45%	121%	830%
Net profit	23	4	154	-82	-99 −530%	-136 −3500%	-9 −106%	-69 +16%
EPS	0.17	0.03	1.16	-0.61	-0.75	-1.02	-0.07	-0.52

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls